eprenetapopt + pegylated liposomal doxorubicin

**Eprenetapopt + pegylated liposomal doxorubicin** is a combination therapy under investigation for cancer treatment. \n- **Eprenetapopt (APR-246)** is a small molecule that reactivates mutant p53 protein, restoring its tumor suppressor function and inducing apoptosis in cancer cells. \n- **Pegylated liposomal doxorubicin** is a chemotherapy drug in which doxorubicin is encapsulated in pegylated liposomes; this formulation prolongs circulation time, enhances tumor delivery via the enhanced permeability and retention effect, and reduces exposure to healthy tissues. Doxorubicin, an anthracycline, inhibits topoisomerase 2, leading to DNA damage and cancer cell death[1][2][4]. \nThe combination is studied primarily in hematological malignancies and solid tumors.

Brand names

Doxil

Other names

APR-246APR246APR 246PRIMA-1METPRIMA1METPRIMA 1METeprenetapoptpegylated liposomal doxorubicindoxorubicin HCl liposomePLD